Home > Oncology > WCLC 2019 > Other Thoracic Malignancies > New Targets in Thymic Epithelial Tumours May Aid in Identifying Treatment Options

New Targets in Thymic Epithelial Tumours May Aid in Identifying Treatment Options

Conference
WCLC 2019

Thymomas and thymic carcinomas (constituting the thymic epithelial tumours [TETs]) are rare epithelial tumours. There are limited treatment options for patients with advanced TETs. The complexity and rarity of the disease hampers the development of effective therapeutics. Next-generation sequencing (NGS) of TETs has confirmed the very low mutational burden and few actionable targets for therapy. Thus, novel strategies are needed for better elucidating the molecular pathways involved in tumour pathogenesis and identification of novel drug targets.

Guha et al. hypothesised that a global proteomics approach may elucidate altered signalling pathways in TETs that can be potentially targeted. To investigate this, 3-state SILAC quantitative mass spectrometry was used to characterise the global proteome and phosphoproteome of TETs, aiming to identify potential actionable drivers in thymomas and thymic carcinomas. Two thymoma (IU-TAB1 and T1682) and three thymic ca...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on